Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00525148 · OUTCOME

Cpre,ss,29

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations · Source last updated 2016-09-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
ng/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
-0:05h (pre-dose) on Day 29

What was measured

Predose concentration of the analyte in plasma at steady state immediately before administration of the 29th dose (Cpre,ss,29).

Analysis population: Treated Set

Groups in this outcome

Afatinib 30 mg

Subjects receiving 30 mg of Afatinib daily.

Afatinib 40 mg

Subjects receiving 40 mg of Afatinib daily.

Afatinib 50 mg

Subjects receiving 50 mg of Afatinib daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Afatinib 30 mg3
Afatinib 40 mg38
Afatinib 50 mg60

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Afatinib 30 mg54.178.5Not reportedNot reportedNot reported
Afatinib 40 mg27.963.1Not reportedNot reportedNot reported
Afatinib 50 mg33.764.1Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        78.5
        value
        54.1
      2. group Id
        OG001
        spread
        63.1
        value
        27.9
      3. group Id
        OG002
        spread
        64.1
        value
        33.7
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      38
    3. group Id
      OG002
      value
      60
    units
    Participants
description
Predose concentration of the analyte in plasma at steady state immediately before administration of the 29th dose (Cpre,ss,29).
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Subjects receiving 30 mg of Afatinib daily.
    id
    OG000
    title
    Afatinib 30 mg
  2. description
    Subjects receiving 40 mg of Afatinib daily.
    id
    OG001
    title
    Afatinib 40 mg
  3. description
    Subjects receiving 50 mg of Afatinib daily.
    id
    OG002
    title
    Afatinib 50 mg
param Type
GEOMETRIC_MEAN
population Description
Treated Set
reporting Status
POSTED
time Frame
-0:05h (pre-dose) on Day 29
title
Cpre,ss,29
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice